Dr. Brendan Mann, Chief Executive Officer of seqSight, leads the company’s strategy, customer discovery, and product development. With deep knowledge of both the scientific domain and customer needs, he is committed to delivering high-quality products and services that bridge the gap between computational and experimental biology.

Dr. Mann guided seqSight’s customer discovery through the NSF I-Corps program, where he developed strategies to align product features with real-world applications. His research background in microbiology and immunology, focused on persistent HIV-1 infection and experience in the U.S. Military HIV Research Program, provides him with a unique perspective on translating scientific insight into practical solutions. At seqSight, he oversees operations, partnerships, and business growth, ensuring that innovation is matched by quality and impact.